Gisele Branchini

Dr. Gisele Branchini

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2012 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
ASAline Francielle Damo Souza
Aline Francielle Damo Souza
IBIlma Simoni Brum
Ilma Simoni Brum
BNBrasil Silva Neto
Brasil Silva Neto
MBMilton Berger
Milton Berger
GBGisele Branchini
Gisele Branchini

1 February 2020 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
BCBruna Pasqualotto Costa
Bruna Pasqualotto Costa
VSVanessa Schein
Vanessa Schein
RZR. Zhao
R. Zhao
ASAndressa Schneiders Santos
Andressa Schneiders Santos
LKLucia Maria Kliemann
Lucia Maria Kliemann
GBGisele Branchini
Gisele Branchini

28 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
BCBruna Pasqualotto Costa
Bruna Pasqualotto Costa
FNFernanda Bordignon Nunes
Fernanda Bordignon Nunes
FNFrancini Corrêa Noal
Francini Corrêa Noal
GBGisele Branchini
Gisele Branchini
Uterine or endometrial cancer (EC) is the sixth most common neoplasia among women worldwide. Cancer can originate from a myriad of causes, and increasing evidence suggests that ion channels (IC) play an important role in the process of carcinogenesis, taking part in many pathways such as self-sufficiency in growth signals, proliferation, evasion of programmed cell death (apoptosis), angiogenesis, cell differentiation, migration, adhesion, and metastasis. Hormones and growth factors are well-known to be involved in the development and/or progression of many cancers and can also regulate some ion channels and pumps. Since the endometrium is responsive and regulated by these factors, the ICs could make an important contribution to the development and progression of endometrial cancer. In this review, we explore what is beyond (ion) flow regulation by investigating the role of the main families of ICs in EC, including as possible targets for EC treatment.

20 October 2020 in Journal of Applied Toxicology
Verified
Journal Article
Open access
PDF file
BCBruna Pasqualotto Costa
Bruna Pasqualotto Costa
MNMarcella Tornquist Nassr
Marcella Tornquist Nassr
FDFernando Mendonça Diz
Fernando Mendonça Diz
LCLeonardo Pfeiff Carlessi
Leonardo Pfeiff Carlessi
KAKrist Antunes
Krist Antunes
JOJarbas Rodrigues de Oliveira
Jarbas Rodrigues de Oliveira
Fructose‐1,6‐bisphosphate (F1,6BP), an intermediate of the glycolytic pathway, has been found to play a promising anticancer effect; nevertheless, the mechanisms involved remain poorly understood. The present study aimed to evaluate the effect and mechanisms of F1,6BP in a human endometrial cancer cell line (Ishikawa). F1,6BP showed an antiproliferative and non‐cytotoxic effect on endometrial cancer cells. These effects are related to the increase in reactive oxygen species (ROS) levels and mitochondrial membrane potential (ΔΨm). These harmful stimuli trigger the upregulation of the expression of pro‐apoptotic genes (p53 and Bax), leading to the reduction of cell proliferation through inducing programmed cell death by apoptosis. Furthermore, F1,6BP‐treated cells had the formation of autophagosomes induced, as well as a decrease in their proliferative capacity after withdrawing the treatment. Our results demonstrate that F1,6BP acts as an anticancer agent through the generation of mitochondrial instability, loss of cell function, and p53‐dependent cell death. Thus, F1,6BP proves to be a potential molecule for use in the treatment against endometrial cancer.

14 September 2024 in Placenta
Verified
Journal Article
Closed access
TMThaís Duarte Borges de Moura
Thaís Duarte Borges de Moura
FNFernanda Bordignon Nunes
Fernanda Bordignon Nunes
BCBianca Dalla Vecchia Crestani
Bianca Dalla Vecchia Crestani
TAThales Fernando Canabarro Araujo
Thales Fernando Canabarro Araujo
EHEduarda Luiza Hanauer
Eduarda Luiza Hanauer
GBGisele Branchini
Gisele Branchini

1 March 2025 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
PDF file
JAJuliana Alves Manhães de Andrade
Juliana Alves Manhães de Andrade
GMGisele Meinerz
Gisele Meinerz
RPRaphael Palma
Raphael Palma
EREduardo Rech
Eduardo Rech
MDMarco Antônio Vinciprova Dall’aGnese
Marco Antônio Vinciprova Dall’aGnese
EKElizete Keitel
Elizete Keitel
Introduction: Acute kidney injury (AKI) in the setting of COVID-19 is associated with worse clinical and renal outcomes, with limited long-term data.